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Introduction
============

Organisms commonly encounter a wide variety of insults, both environmental and pathological. Many such insults, including heat shock, heavy-metal toxins, acidosis, ischemia/reperfusion, and oxidative damage, disturb cellular proteostasis and trigger the proteotoxic stress response (PSR), or heat shock response (Lindquist, [@b43]; Westerheide & Morimoto, [@b68]). This stress response is predominantly controlled by a transcription factor named heat shock factor 1 (HSF1) and is hallmarked by a drastic induction of heat shock proteins (HSPs) (Lindquist, [@b43]; Morimoto, [@b47]). HSPs are molecular chaperones, proteins that assist protein folding, trafficking, and degradation and thereby guard the proteome against the danger of misfolding and aggregation (Lindquist, [@b43]; Welch, [@b67]). Thus, this stress response plays an essential role in preserving proteostasis and enhancing survival in the face of such stressors, antagonizes neurodegeneration, and prolongs normal lifespan (Hsu *et al*, [@b29]; Balch *et al*, [@b2]; Dai *et al*, [@b12]; Kondo *et al*, [@b38]; Lin *et al*, [@b42]; Pierce *et al*, [@b52]). Contrasting sharply with these broadly acclaimed benefits, our and others\' recent studies have begun to reveal a surprising action of the HSF1-mediated stress response, whereby it is hijacked by malignant cells and facilitates oncogenesis (Dai *et al*, [@b10], [@b12]; Min *et al*, [@b46]; Meng *et al*, [@b45]; Jin *et al*, [@b33]; Scott *et al*, [@b56]).

Despite its evident importance in biology and human diseases, our understanding of the mechanisms through which this ancient adaptive stress response is regulated remains incomplete. In particular, little is known of how the PSR interacts with other cellular stress responses. One of such responses is the metabolic stress response that critically maintains cellular energy homeostasis. Metabolic stressors, through raising intracellular AMP/ATP ratios, instigate a low cellular energy state. By sensing increased AMP/ATP ratios, AMP-activated protein kinase (AMPK), a master metabolic regulator, becomes mobilized (Hardie, [@b25]). Mammalian AMPK is a protein complex comprising one catalytic α-subunit and two regulatory subunits: β and γ (Hardie, [@b25]). Upon activation, AMPK phosphorylates a wide array of downstream effectors to enhance ATP generation and reduce ATP expenditure (Hardie, [@b25]). This function of AMPK has proven crucial for cells to survive metabolic stress.

Herein, we report a novel interplay between the metabolic stress sensor AMPK and the proteotoxic stress sensor HSF1 and show that it has profound impacts on stress resistance, proteostasis, and tumor growth.

Results
=======

Metformin suppresses the HSF1-mediated PSR
------------------------------------------

In order to infer small molecules that potentially modulate the HSF1-mediated PSR, we queried the Connectivity Map ([www.broadinstitute.org/cmap](http://www.broadinstitute.org/cmap)), a collection of gene expression profiles from human cells treated with bioactive molecules (Lamb *et al*, [@b40]), with a gene signature that was identified in human breast cancer cells following *HSF1* knockdown (Santagata *et al*, [@b55]). As expected, perturbagens known to activate HSF1, including the proteasome inhibitor MG-262 and HSP90 inhibitors (alvespimycin, tanespimycin, and monorden), generate gene expression patterns opposite to the query HSF1-inactivation gene signature (Fig[1A](#fig01){ref-type="fig"}). In contrast, two translation inhibitors, cephaeline and emetine, generate expression patterns enriched for the query gene signature, congruent with their roles in suppressing HSF1 activation (Santagata *et al*, [@b55]). Intriguingly, metformin, a metabolic stressor and the most frequently prescribed medication for type II diabetes mellitus (T2D) worldwide (Dowling *et al*, [@b14]), also provokes gene expression changes concordant with HSF1 inactivation (Fig[1A](#fig01){ref-type="fig"}).

![Metformin suppresses the HSF1-mediated PSR A The connectivity map suggests that metformin generates a gene expression pattern concordant with HSF1 inactivation. Perturbagens inducing and reversing the biological state encoded in the query signature are assigned positive and negative enrichment scores, respectively.B Following treatment with 10 mM metformin overnight, NIH3T3 reporter cells were heat-shocked at 43°C for 30 min and recovered at 37°C for 5 h. GFP induction was quantitated by flow cytometry. HS: heat shock.C Individual proteins in reporter cells treated with and without 10 mM metformin overnight were detected by immunoblotting.D, E Following heat shock and recovery for 4 h, mRNA levels in reporter cells treated with and without 10 mM metformin overnight were quantitated by qRT--PCR (mean ± SD, *n *=* *3, Student\'s *t*-test, \*\**P *\<* *0.01, \*\*\**P *\<* *0.001). β-actin was used as the internal control.F Reporter cells were treated with 10 mM metformin overnight, and viability was measured using Guava ViaCount® reagents (mean ± SD, *n *=* *5, n.s., not significant, Student\'s *t*-test).G Left panel, graphic depiction of the ELISA-based DNA binding assay. HSE: heat shock element. Right panel: Immediately following heat shock at 43°C for 30 min, nuclear proteins of the reporter cells treated with and without 10 mM metformin were extracted for assay (mean ± SD, *n *=* *3, Student\'s *t*-test, \*\**P *\<* *0.01, \*\*\**P *\<* *0.001). Experimental details are described in Materials and Methods.H Graphic depiction of the adapted PLA. A pair of primary antibodies recognizes DNA-bound HSF1s and dsDNAs, respectively.I HEK293T cells stably expressing a scramble or *HSF1*-targeting shRNA were treated with 10 mM metformin overnight and heat-shocked at 43°C for 30 min. Cells were fixed for PLA to detect HSF1--DNA interactions. Experimental details are described in Materials and Methods. Scale bars: 50 μm for low magnification and 10 μm for high magnification.J Immediately following heat shock, cytoplasmic and nuclear proteins of the reporter cells treated with and without 10 mM metformin were extracted for immunoblotting. LDH and Lamin A/C were used as cytoplasmic and nuclear markers, respectively. C: cytoplasm; N: nucleus.K Reporter mice (ventral side shown) were pre-treated with metformin for 3 days, 2 mg/mouse/day, via i.p. injection. Following a single i.p. injection of velcade (5 mg/kg) and recovery for 6 h, whole-body luciferase activities were quantitated by bioluminescence imaging. The photon flux of each mouse was expressed as photon/s/cm^2^/steradian (right panel, mean ± SD, *n *=* *3, one-way ANOVA, \**P *\<* *0.05; \*\**P *\<* *0.01).\
Source data are available online for this figure.](embj0034-0275-f1){#fig01}

Next, we experimentally verified the metformin-mediated suppression of the PSR by testing the ability of metformin to suppress heat shock-induced HSP expression. For HSP expression, we used an NIH3T3 reporter cell line that stably expresses a GFP-firefly luciferase fusion controlled by the human *HSP70B* (*HSPA6*) promoter (Dai *et al*, [@b12]). As expected, heat shock-induced GFP expression in phosphate-buffered saline (PBS)-treated cells and metformin markedly blocked this induction (Fig[1B](#fig01){ref-type="fig"}). Metformin also impaired induction of endogenous HSP72 and HSP25 proteins (Fig[1C](#fig01){ref-type="fig"}), two classic stress-inducible HSPs. Congruent with transcriptional suppression by metformin, induction of *Hsp72* (*Hspa1a*) and *Hsp25* (*Hspb1*) mRNAs by heat shock was markedly impaired in metformin-treated cells compared to control cells (Fig[1D](#fig01){ref-type="fig"} and [E](#fig01){ref-type="fig"}). While these notable effects were achieved using 10 mM metformin, a similar pattern of changes, albeit to a lesser extent (Supplementary [Fig S1A](#sd1){ref-type="supplementary-material"} and [B](#sd1){ref-type="supplementary-material"}), was also observed for 10 μM metformin, a concentration comparable to that found in the blood of T2D patients (Sum *et al*, [@b59]; Lalau *et al*, [@b39]; Dowling *et al*, [@b15]). Importantly, this defect in the PSR was not due to impaired cell viability following metformin treatment (Fig[1F](#fig01){ref-type="fig"}).

To demonstrate impaired HSF1 activation, we directly examined HSF1--DNA binding. To accomplish this, we developed a new enzyme-linked immunosorbent assay (ELISA)-based technique to measure HSF1--DNA binding capability (Fig[1G](#fig01){ref-type="fig"}, left panel). In this assay, nuclear HSF1 proteins competent for DNA binding are captured by ideal heat shock element (HSE) oligonucleotides that are pre-immobilized on a microtiter plate through biotin--avidin interactions. Subsequently, a specific primary antibody recognizes the DNA-bound HSF1 proteins, followed by detection with secondary antibodies. As expected, HSF1--DNA binding was markedly increased following heat shock (Supplementary [Fig S1C](#sd1){ref-type="supplementary-material"}); however, metformin evidently blocked this increase (Fig[1G](#fig01){ref-type="fig"}, right panel).

While our new method is quantitative and high-throughput, it requires, similar to the prevailing chromatin IP (ChIP) technique, a large amount of DNA and provides only average values for a given cell population. To provide more detailed information on HSF1--DNA binding, we adapted the newly emerged proximity ligation assay (PLA) technique to visualize endogenous physical associations between HSF1 and genomic DNAs at the single-cell level. By means of two species-specific secondary antibodies conjugated with oligonucleotides, PLA converts protein--protein interactions in proximity into DNA signals (Clausson *et al*, [@b7]). We extended this technique to detect HSF1--DNA interactions *in situ* by utilizing a mouse anti-double-stranded DNA antibody in conjunction with a rabbit anti-HSF1 antibody (Fig[1H](#fig01){ref-type="fig"}). The specificity of antibodies was validated by standard immunostaining. In HEK293T cells, the DNA antibody generated similar staining patterns with and without heat shock (Supplementary [Fig S1D](#sd1){ref-type="supplementary-material"}). This staining largely overlaid with that of the DNA dye DAPI, indicating a predominant DNA labeling irrespective of heat shock. Importantly, this staining was markedly reduced following DNase treatment (Supplementary [Fig S1E](#sd1){ref-type="supplementary-material"}), indicating specific DNA labeling. As a negative control, HEK293T cells stably expressing *HSF1*-targeting shRNAs did not display notable HSF1 staining (Supplementary [Fig S1F](#sd1){ref-type="supplementary-material"}). Congruently, no specific PLA signals were detected in these *HSF1*-deficient cells (Fig[1I](#fig01){ref-type="fig"}, left panel). In cells expressing scramble shRNAs and without heat shock, only sporadic PLA signals, manifested as distinct nuclear foci, were observed (Fig[1I](#fig01){ref-type="fig"}, right panel), indicating basal constitutive HSF1 activation. In contrast, heat shock greatly increased these signals, demonstrated by numerous bright nuclear foci (Fig[1I](#fig01){ref-type="fig"}, right panel). Importantly, metformin potently blocked this increase (Fig[1I](#fig01){ref-type="fig"}, right panel), demonstrating impaired *in vivo* HSF1--DNA binding by metformin.

HSF1 activation is a multi-step process, involving phosphorylation, nuclear translocation, and DNA binding. Next, we investigated whether metformin affected HSF1 nuclear translocation, a prerequisite for its DNA binding. As expected, heat shock caused most HSF1 proteins to translocate from the cytoplasm to the nucleus (Fig[1J](#fig01){ref-type="fig"}). Importantly, metformin impeded this translocation (Fig[1J](#fig01){ref-type="fig"}). Thus, metformin impairs HSF1--DNA binding at least in part through blockade of its nuclear translocation.

To determine whether metformin impairs the PSR at the organismal level, we utilized transgenic mice that express dual reporter genes, firefly luciferase and EGFP, both controlled by the mouse *Hsp72* promoter (O\'Connell-Rodwell *et al*, [@b50]). When analyzed with bioluminescence imaging, these mice enable noninvasive surveillance of the PSR *in vivo*. Under non-stress conditions, these reporter mice exhibited basal luciferase activities in mouth and limbs (Fig[1K](#fig01){ref-type="fig"}; Supplementary [Fig S1G](#sd1){ref-type="supplementary-material"}). As expected, challenge with the proteasome inhibitor velcade, a potent proteotoxic stressor, markedly increased whole-body luciferase activities. However, pre-treatment with metformin impaired the velcade-induced elevation of luciferase activities (Fig[1K](#fig01){ref-type="fig"}; Supplementary [Fig S1G](#sd1){ref-type="supplementary-material"}). Together, these results indicate that metformin suppresses the PSR through inactivation of HSF1.

AMPK negatively regulates HSF1 activation via phosphorylation
-------------------------------------------------------------

We next sought to elucidate the molecular mechanisms by which metformin inactivates HSF1. Through diminishment of mitochondrial ATP production, metformin activates AMPK, a key cellular sensor of metabolic stress (El-Mir *et al*, [@b17]). This activation is known to mediate numerous effects of metformin (Kahn *et al*, [@b36]). However, it has also been reported that metformin inhibits mTORC1 independently of AMPK (Kalender *et al*, [@b37]).

We first asked whether mTORC1 inhibition by metformin mediates HSF1 suppression. To address this, we examined induction of *Hsp* genes in cells treated with rapamycin, a specific mTOR inhibitor. Successful inhibition of mTORC1 by rapamycin was evidenced by a marked reduction of S6K1 phosphorylation (Supplementary [Fig S2A](#sd1){ref-type="supplementary-material"}). In stark contrast to metformin, in our experiments, rapamycin enhanced *Hsp* induction by heat shock (Supplementary [Fig S2B](#sd1){ref-type="supplementary-material"} and [C](#sd1){ref-type="supplementary-material"}), arguing against mTORC1 inhibition as a primary cause of HSF1 suppression by metformin. This result somewhat contrasts with a recent report, indicating that rapamycin suppressed HSF1 activation (Chou *et al*, [@b6]). Surprisingly, our results showed that whereas high doses of rapamycin suppressed HSF1, low doses activated HSF1 (unpublished observations), suggesting indirect regulation of HSF1 by mTORC1. As expected, metformin induced AMPK activation, evidenced by elevated Thr172 phosphorylation of AMPKα (Supplementary [Fig S2A](#sd1){ref-type="supplementary-material"}; Hawley *et al*, [@b26]). Moreover, two other mechanistically distinct AMPK activators, A-769662 and aminoimidazole carboxamide ribonucleotide (AICAR) (Corton *et al*, [@b9]; Göransson *et al*, [@b21]), also impaired the PSR (Fig[A](#fig02){ref-type="fig"} and [B](#fig02){ref-type="fig"}; Supplementary [Fig S2D](#sd1){ref-type="supplementary-material"}). A-769662 is a direct and specific AMPK activator, causing phosphorylation of the well-characterized AMPK substrate acetyl-CoA carboxylase (ACC) (Fig[2C](#fig02){ref-type="fig"}; Göransson *et al*, [@b21]). These results suggest AMPK as a common mediator of HSF1 suppression.

![AMPK suppresses HSF1 activation through physical interaction A-C Reporter cells were treated with and without 1 μM A-769662 for 3 h followed by heat shock at 43°C for 30 min and recovery at 37°C for 5 h. *Hspa1a* and *Hspb1* mRNA levels were quantitated by qRT--PCR (mean ± SD, *n *=* *3, Student\'s *t*-test, \*\*\**P *\<* *0.001). ACC phosphorylation was detected by immunoblotting (C).D-F Primary MEFs were derived from *Ampk*α*1*^*fl/fl*^; *Ampk*α*2*^*fl/fl*^ embryos and transduced with either adenoviral GFP or Cre to delete *Ampk*α*1/2 in vitro*. AMPKα levels were detected 4 days after transductions (D). Following viral transductions, *Hsp* mRNA levels were quantitated by qRT--PCR in MEFs with and without 10 mM metformin treatment overnight followed by 43°C heat shock for 30 min and recovery for 4 h (mean ± SD, *n *=* *3, one-way ANOVA, n.s., not significant, \**P *\<* *0.05, \*\**P *\<* *0.01, \*\*\**P *\<* *0.001).G Transcriptional activities of HSF1 were measured by a dual reporter system consisting of two plasmids: the HSF1-dependent reporter pHSE-SEAP, in which ideal HSEs drive the expression of secreted alkaline phosphatase (SEAP), and the control reporter pCMV-*Gaussia* Luc, in which a CMV promoter drives the expression of secreted *Gaussia* luciferase. In HEK293T cells, either LacZ or GST-AMPKα1^CA^ plasmid was co-transfected with the two reporter plasmids. After 24 h, the transfected cells were heat-shocked at 44°C for 45 min. The culture supernatants were collected to measure SEAP and luciferase activities 24 h after heat shock. SEAP signals were normalized to *Gaussia* luciferase signals (mean ± SD, *n *=* *5, Student\'s *t*-test, \*\**P *\<* *0.01, \*\*\**P *\<* *0.001).H, I Following treatment with 10 mM metformin overnight, endogenous AMPKα and HSF1 proteins were co-precipitated using anti-AMPKα agarose conjugates from lysates of immortalized *Hsf1*^*+/+*^ MEFs (H). HC: heavy chain. Endogenous HSF1-AMPKα interactions in immortalized *Hsf1*^*+/+*^ and *Hsf1*^*−/−*^ MEFs were visualized *in situ* by PLA (I). Experimental details are described in Materials and Methods. Scale bars: 50 μm.\
Source data are available online for this figure.](embj0034-0275-f2){#fig02}

To directly test this, we conditionally deleted the two *Ampk*α isoforms, α*1* and α*2*, in mouse embryonic fibroblasts (MEFs) through adenoviral Cre recombinase (Fig[2D](#fig02){ref-type="fig"}). Compared to GFP transduction, Cre transduction in *Ampk*α*1/2*^*fl/fl*^ MEFs not only enhanced *Hsp* induction by heat shock but also markedly blocked metformin-induced *Hsp* suppression (Fig[2E](#fig02){ref-type="fig"} and [F](#fig02){ref-type="fig"}), indicating the necessity of AMPK for metformin-mediated HSF1 inactivation. The incomplete blockade of metformin effect was likely due to residual AMPKα proteins (Fig[2D](#fig02){ref-type="fig"}) and/or AMPK-independent mechanisms of metformin. To determine the sufficiency of AMPK activation for HSF1 suppression, we activated AMPK signaling through expression of a GST-tagged constitutively active mutant of the α1-subunit, AMPKα^CA^ (Egan *et al*, [@b16]). AMPK activation was evidenced by elevated phosphorylation of RAPTOR, a known cellular substrate for AMPK (Gwinn *et al*, [@b24]), at Ser792 (Supplementary [Fig S2E](#sd1){ref-type="supplementary-material"}). Under both basal and heat shock conditions, this mutant impaired activation of the HSF1 reporter (Fig[2G](#fig02){ref-type="fig"}), demonstrating that AMPK activation alone is sufficient to repress the transcriptional activity of HSF1. Together, these results indicate a negative regulation of the PSR by AMPK.

We reasoned that AMPK might directly phosphorylate HSF1. To test this, we first examined potential physical interactions between AMPK and HSF1 by co-immunoprecipitation (co-IP). As a positive control, while some endogenous ACC proteins were co-precipitated with endogenous AMPKα in MEFs under basal conditions, metformin markedly enhanced this co-IP (Fig[2H](#fig02){ref-type="fig"}). Importantly, in a similar pattern, endogenous HSF1 proteins were also co-precipitated with AMPKα (Fig[2H](#fig02){ref-type="fig"}). In HEK293T cells, exogenous FLAG-HSF1 proteins were also co-precipitated with GST-AMPKα^CA^ (Supplementary [Fig S2F](#sd1){ref-type="supplementary-material"}), indicating specific *in vivo* physical AMPK--HSF1 interactions. This interaction was then confirmed *in situ* by PLA. Using a rabbit antibody recognizing Thr172-phosphorylated AMPKα in conjunction with a mouse monoclonal anti-HSF1 antibody, we visualized endogenous AMPK--HSF1 interactions in *Hsf1*^*+/+*^ MEFs. *Hsf1*^−/−^ MEFs served as negative controls. As expected, no specific PLA signals were observed in *Hsf1*^−*/*−^ MEFs, irrespective of metformin treatment (Fig[2I](#fig02){ref-type="fig"}). While only faint signals were detected in *Hsf1*^*+/+*^ cells treated with PBS, metformin treatment markedly augmented these signals (Fig[2I](#fig02){ref-type="fig"}), indicating a specific and inducible interaction between endogenous HSF1 and AMPK proteins.

We next asked whether AMPK inactivates HSF1 through phosphorylation. The protein motif algorithm ScanSite (<http://scansite.mit.edu/>) predicted a potential phosphorylation site on HSF1 at serine 121 residue (Supplementary [Fig S3A](#sd1){ref-type="supplementary-material"}). To test this, we took advantage of a phosphorylation-specific antibody. The specificity of this antibody was validated using a phosphorylation-resistant mutant, HSF1^S121A^, in *HSF1*-deficient HEK293T cells. This antibody readily detected exogenously expressed HSF1^WT^ under basal conditions and metformin treatment enhanced this signal (Fig[3A](#fig03){ref-type="fig"}). In contrast, the same antibody failed to detect exogenously expressed HSF1^S121A^ mutants under both basal and metformin treatment conditions (Fig[3A](#fig03){ref-type="fig"}). Moreover, this antibody did not detect specific signals in *Hsf1*^−*/*−^ MEFs (Supplementary [Fig S3B](#sd1){ref-type="supplementary-material"}). Importantly, both *Ampk*α*1/2* deletion and *AMPK*α*1/2* knockdown largely blocked HSF1 Ser121 phosphorylation induced by metformin or A-769662 (Fig[3B](#fig03){ref-type="fig"}; Supplementary [Fig S3C](#sd1){ref-type="supplementary-material"}), demonstrating the necessity of AMPK for this phosphorylation *in vivo*. Conversely, AMPKα^CA^ sufficed to induce Ser121 phosphorylation of HSF1^WT^, but not HSF1^S121A^ (Fig[3C](#fig03){ref-type="fig"}). Previously, it was reported that MAPK-activated protein kinase 2 (MK2) could phosphorylate the same site (Wang *et al*, [@b66]). However, *MK2* knockdown failed to significantly block HSF1 Ser121 phosphorylation induced by metformin (Supplementary [Fig S3D](#sd1){ref-type="supplementary-material"} and [E](#sd1){ref-type="supplementary-material"}), indicating that MK2 is not important for this modification induced by metformin.

![AMPK phosphorylates Ser121 to inactivate HSF1 A In HEK293T cells that stably express an shRNA targeting the 3′ UTR of human *HSF1*, HSF1^WT^ or HSF1^S121A^ was expressed. Following treatment with 10 mM metformin overnight, the levels of HSF1 phosphorylation at Ser121 were detected by immunoblotting using a specific phospho-HSF1 Ser121 antibody (A8041, Assay Biotechnology).B Primary *Ampk*α*1*^*fl/fl*^; *Ampk*α*2*^*fl/fl*^ MEFs were transduced with adenoviral GFP or Cre. Following treatment with 10 mM metformin overnight or treatment with 10 μM A-769662 for 3 h, HSF1 Ser121 phosphorylation was examined by immunoblotting.C HSF1^WT^ or HSF1^S121A^ was co-expressed with either GFP or GST-AMPKα^CA^ in *HSF1*-deficient HEK293T cells. HSF1 Ser121 phosphorylation was examined by immunoblotting.D AMPK complexes were immunoprecipitated from HEK293T cells treated with and without 10 mM metformin overnight. Aliquots of AMPK complexes were incubated with 400 ng purified recombinant His-tagged HSF1 proteins with and without 100 μM AMP or 20 μM compound C (CC). HSF1 Ser121 phosphorylation was detected by immunoblotting.E, F HSF1 activities were measured by the dual reporter system in *HSF1*-deficient HEK293T cells. Either FLAG-HSF1^WT^ or FLAG-HSF1^S121A^ was co-expressed with LacZ or AMPKα1^CA^ (E). Following expression of HSF1^WT^ or HSF1^S121A^, cells were treated with and without 10 mM metformin overnight (F) (mean ± SD, *n *=* *5, one-way ANOVA, n.s., not significant, \**P *\<* *0.05, \*\**P *\<* *0.01, \*\*\**P *\<* *0.001).G, H FLAG-HSF1^WT^ or FLAG-HSF1^S121A^ plasmids were co-transfected with LacZ or AMPKα1^CA^ plasmids into *HSF1*-deficient HEK293T cells for 3 days (G). Following transfection with FLAG-HSF1^WT^ or FLAG-HSF1^S121A^ plasmids for 3 days, *HSF1*-deficient HEK293T cells were treated with and without 10 mM metformin overnight (H). Nuclear proteins were extracted to measure HSF1--DNA binding by the ELISA-based DNA binding assay using anti-FLAG antibodies (mean ± SD, *n *=* *3, one-way ANOVA, n.s., not significant, \**P *\<* *0.05, \*\**P *\<* *0.01, \*\*\**P *\<* *0.001).I, J Following transfections and metformin treatment as described in (G) and (H), cytoplasmic and nuclear proteins were extracted for immunoblotting using anti-FLAG antibodies.\
Source data are available online for this figure.](embj0034-0275-f3){#fig03}

To address whether AMPK directly phosphorylates HSF1, we conducted *in vitro* kinase assays using immunoprecipitated AMPK complexes. Compared to IgG controls, precipitates of AMPKα antibodies weakly phosphorylated recombinant HSF1 proteins at Ser121 in the absence of AMP (Fig[3D](#fig03){ref-type="fig"}). However, AMP markedly enhanced this phosphorylation and the AMPK inhibitor compound C blocked this event (Fig[3D](#fig03){ref-type="fig"}; Zhou *et al*, [@b71]), indicating a specific action of AMPK. Congruent with its activation, AMPK complexes precipitated from metformin-treated cells more efficiently phosphorylated HSF1 (Fig[3D](#fig03){ref-type="fig"}). Importantly, compared to its wild-type counterparts HSF1^S121A^ mutants not only exhibited higher basal transcriptional activities but also were refractory to AMPKα^CA^- and metformin-mediated suppression (Fig[3E](#fig03){ref-type="fig"} and [F](#fig03){ref-type="fig"}). In line with their transcriptional activities, HSF1^WT^ and HSF1^S121A^ exhibited differential DNA bindings (Fig[3G](#fig03){ref-type="fig"} and [H](#fig03){ref-type="fig"}), demonstrating the importance of Ser121 phosphorylation to HSF1 suppression by AMPK. While both FLAG-HSF1^WT^ and FLAG-HSF1^S121A^ proteins were expressed at comparable levels in HEK293T cells under basal conditions, overnight metformin treatment slightly decreased HSF1^WT^, but not HSF1^S121A^ proteins (Supplementary [Fig S3F](#sd1){ref-type="supplementary-material"} and [G](#sd1){ref-type="supplementary-material"}). This reduction likely contributes to metformin-induced HSF1 suppression and suggests a role of Ser121 phosphorylation in HSF1 stability. Indeed, cyclohexamide chase experiments revealed that metformin treatment for 24 h accelerated HSF1 turnover and S121A mutation markedly mitigated this effect (Supplementary [Fig S3H](#sd1){ref-type="supplementary-material"}). Interestingly, in contrast to metformin, AMPKα^CA^ expression did not reduce HSF1^WT^ levels (Supplementary [Fig S3F](#sd1){ref-type="supplementary-material"}). These results suggest that Ser121 phosphorylation is necessary but not sufficient to destabilize HSF1 and that additional mechanisms may be involved in metformin-induced HSF1 instability. Despite no impacts on HSF1 expression, AMPKα^CA^ impaired constitutive nuclear translocation of HSF1^WT^ in HEK293T cells, indicated by diminished nuclear--cytoplasmic ratio of HSF1 levels (Fig[3I](#fig03){ref-type="fig"}). S121A mutation not only enhanced HSF1 nuclear translocation under basal conditions but also rendered HSF1 resistant to the effect of AMPKα^CA^ (Fig[3I](#fig03){ref-type="fig"}). Similarly, while metformin impaired HSF1^WT^ nuclear translocation, it exerted little effect on HSF1^S121A^ mutants (Fig[3J](#fig03){ref-type="fig"}). Thus, this defect in nuclear translocation due to Ser121 phosphorylation at least in part contributes to reduced HSF1--DNA binding. In summary, these results indicate that activated AMPK physically interacts with HSF1 and suppresses its activity primarily via Ser121 phosphorylation.

Metabolic stress suppresses the PSR
-----------------------------------

In response to metabolic stress, AMPK is mobilized to sustain cellular energy homeostasis and improve survival (Kahn *et al*, [@b36]). In light of the inactivation of HSF1 by AMPK that we discovered, we next asked whether metabolic stress impacts the cellular response to proteotoxic stress. To provoke metabolic stress, we applied either leucine or glucose deprivation to the NIH3T3 heat shock reporter cells described above. Similar to metformin treatment, deprivation of each nutrient suppressed GFP induction by heat shock (Fig[4A](#fig04){ref-type="fig"} and [B](#fig04){ref-type="fig"}). This suppression was not due to impaired cell viability following nutrient deprivation (Supplementary [Fig S4A](#sd1){ref-type="supplementary-material"} and B). Mechanistically, nutrient deprivation impaired HSF1--DNA binding following heat shock (Fig[4C](#fig04){ref-type="fig"} and [D](#fig04){ref-type="fig"}), thereby impairing HSP induction (Fig[4E](#fig04){ref-type="fig"} and [F](#fig04){ref-type="fig"}). Congruent with diminished protein-chaperoning capacity following nutrient deprivations, protein Lys48 polyubiquitination, a key modification targeting proteins for proteasomal degradation and a surrogate indicator of protein misfolding (Pickart & Eddins, [@b51]), was aggravated under both basal and heat shock conditions (Fig[4E](#fig04){ref-type="fig"} and [F](#fig04){ref-type="fig"}). In stark contrast, both nutrient deprivations induced expression of BiP/GRP78 (Fig[4E](#fig04){ref-type="fig"} and [F](#fig04){ref-type="fig"}), a key endoplasmic reticulum (ER) chaperone and marker of the unfolded protein response (UPR), which responds to ER stress (Walter & Ron, [@b64]). Together, these results indicate that nutrient deprivations trigger the UPR but, intriguingly, suppress the PSR. As expected, both nutrient deprivations induced AMPKα Thr172 phosphorylation in NIH3T3 and HEK293 cells (Fig[4G](#fig04){ref-type="fig"} and [H](#fig04){ref-type="fig"}; Supplementary [Fig S4C](#sd1){ref-type="supplementary-material"} and [D](#sd1){ref-type="supplementary-material"}). Congruent with HSF1 phosphorylation by AMPK, both nutrient deprivations also induced HSF1 Ser121 phosphorylation (Fig[4G](#fig04){ref-type="fig"} and [H](#fig04){ref-type="fig"}; Supplementary [Fig S4C](#sd1){ref-type="supplementary-material"} and [D](#sd1){ref-type="supplementary-material"}). Of note, 4-h leucine starvation was required to induce evident AMPK phosphorylation (Fig[4G](#fig04){ref-type="fig"}; Supplementary [Fig S4C](#sd1){ref-type="supplementary-material"}). These findings not only agree with HSF1 inactivation by AMPK (Fig[2](#fig02){ref-type="fig"}), but also suggest AMPK activation as a common mechanism underlying the inhibitory effect of metabolic stress on the PSR.

![Metabolic stress suppresses the PSR through AMPK A, B NIH3T3 reporter cells were cultured overnight in DMEM with and without leucine (A) or 4.5 g/l glucose (B). Following heat shock at 43°C for 30 min and recovery for 5 h, GFP induction was quantitated by flow cytometry.C, D Nuclear proteins were extracted from reporter cells with and without nutrient deprivations overnight for the ELISA-based DNA binding assay (mean ± SD, *n *=* *3, Student\'s *t*-test, \**P *\<* *0.05, \*\**P *\<* *0.01, \*\*\**P *\<* *0.001).E, F Following nutrient deprivations overnight, the reporter cells were heat-shocked at 43°C for 30 min and recovered overnight. Individual proteins were detected by immunoblotting.G, H Reporter cells were subjected to nutrient starvation for the indicated time. AMPKα Thr172 and HSF1 Ser121 phosphorylation was measured by immunoblotting.I, J HEK293T cells were sequentially transfected with control or *AMPK*α*1/2*-targeting siRNAs and dual HSF1 reporter plasmids. 24 h later, transfected cells were starved overnight before reporter activities were measured (mean ± SD, *n *=* *6, Student\'s *t*-test, n.s., not significant, \*\**P *\<* *0.01, \*\*\**P *\<* *0.001).K, L FLAG-HSF1^WT^ or FLAG-HSF1^S121A^ plasmids were co-transfected with the dual HSF1 reporter plasmids into *HSF1*-deficient HEK293T cells for 2 days, followed by overnight starvation (mean ± SD, *n *=* *5, Student\'s *t*-test, n.s., not significant, \**P *\<* *0.05, \*\**P *\<* *0.01).\
Source data are available online for this figure.](embj0034-0275-f4){#fig04}

Suppression of HSF1 activation by nutrient deprivations was further confirmed in HEK293 cells. Importantly, *AMPK*α*1/2* knockdown not only elevated basal HSF1 activity but also reversed HSF1 suppression imposed by nutrient deprivations (Fig[4I](#fig04){ref-type="fig"} and [J](#fig04){ref-type="fig"}). It has been known that AMPK activation inhibits mTORC1 (Gwinn *et al*, [@b24]). To determine whether mTORC1 inhibition following nutrient deprivations plays an important role in HSF1 inactivation, we measured HSF1 transcriptional activities under nutrient deprivations in the presence of high doses of rapamycin. While 500 nM rapamycin alone suppressed HSF1, combined nutrient deprivation further inactivated HSF1 (Supplementary [Fig S4E](#sd1){ref-type="supplementary-material"}), strongly suggesting that AMPK activation induced by nutrient deprivations is capable of suppressing HSF1 independently of mTORC1. Congruent with a direct regulatory mechanism, S121A mutation rendered HSF1 resistant to nutrient deprivation-mediated suppression (Fig[4K](#fig04){ref-type="fig"} and [L](#fig04){ref-type="fig"}). Together, these results reveal that metabolic stress antagonizes the HSF1-mediated PSR, wherein AMPK activation plays an important role via phosphorylating HSF1 at Ser121.

Proteotoxic stress suppresses AMPK
----------------------------------

In stark contrast to metabolic stress, our results revealed that heat shock markedly diminished AMPK Thr172 phosphorylation (Fig[5A](#fig05){ref-type="fig"} and Supplementary [Fig S5A](#sd1){ref-type="supplementary-material"}). In parallel, HSF1 Ser121 phosphorylation was also reduced under heat shock (Fig[5A](#fig05){ref-type="fig"} and Supplementary [Fig S5A](#sd1){ref-type="supplementary-material"}), suggesting AMPK inactivation. This was confirmed by *in vitro* kinase assays. Compared to AMPK complexes immunoprecipitated from cells without heat shock, complexes from heat-shocked cells exhibited markedly impaired capability to phosphorylate recombinant ACC1 proteins *in vitro* even in the presence of AMP (Fig[5B](#fig05){ref-type="fig"}). Congruent with this defect, heat shock caused a specific reduction of γ2-subunit within immunoprecipitated AMPK complexes (Fig[5B](#fig05){ref-type="fig"}). AMPKγ subunits play a critical role in binding AMP/ATP, and mutations in γ2-subunit are associated with cardiac hypertrophy (Blair *et al*, [@b3]; Hardie, [@b25]). To our surprise, 30-min heat shock sufficed to diminish total cellular γ2-subunits (Fig[5B](#fig05){ref-type="fig"}). We reasoned that this reduction was likely due to protein instability. In support of this notion, an increase in γ2-subunit was detected in detergent-insoluble fractions of cellular protein extracts and a simultaneous decrease in this subunit was detected in detergent-soluble fractions (Fig[5C](#fig05){ref-type="fig"}), suggesting oligomerization and/or aggregation of γ2-subunits under heat shock conditions. Thus, our results indicate that, at least through regulation of Thr172 phosphorylation of α-subunits and destabilization of γ-subunits, heat shock suppresses AMPK.

![Heat shock suppresses AMPK and interferes with cellular responses to metabolic stressors A Reporter cells were heat-shocked at 43°C for the indicated time. AMPKα Thr172 and HSF1 Ser121 phosphorylation was measured by immunoblotting.B Immediately following heat shock at 43°C for 40 min, AMPK complexes were immunoprecipitated from HEK293 cells and *in vitro* kinase assays were performed as described in Figure 3D using recombinant human ACC1 proteins as substrates.C Following heat shock at 43°C for 40 min, both detergent-soluble and detergent-insoluble fractions of cellular proteins were extracted from HEK293 cells as described in Materials and Methods for immunoblotting.D, E Immediately following heat shock at 43°C for 40 min, HEK293 cells were subjected to nutrient deprivations for 4 h. AMPKα Thr172 and ACC Ser79 phosphorylation was measured by immunoblotting.F-H HSF1^WT^ or HSF1^S121A^ plasmids were transfected into *HSF1*-deficient HEK293T cells. Transfected cells were heat-shocked at 43°C for 40 min. *HSP* mRNAs were quantitated by qRT--PCR following overnight recovery. HSF1--DNA binding was measured immediately after heat shock (mean ± SD, *n *=* *3, Student\'s *t*-test, \*\**P *\<* *0.01, \*\*\**P *\<* *0.001).I Schematic depiction of the opposite impacts of metabolic and proteotoxic stress on AMPK and HSF1. While metabolic stress activates AMPK to suppress HSF1, proteotoxic stress suppresses AMPK to enhance HSF1 activation. Dashed arrow signifies HSF1 activation independent of AMPK.\
Source data are available online for this figure.](embj0034-0275-f5){#fig05}

Given the pivotal role of AMPK in mediating the metabolic stress response, we were curious to know whether proteotoxic stress could interfere with cellular responses to metabolic stressors. Consistent with its inhibitory effect on AMPK, transient heat shock immediately proceeding nutrient deprivations significantly impaired induction of AMPK and ACC phosphorylation (Fig[5D](#fig05){ref-type="fig"} and [E](#fig05){ref-type="fig"}), suggesting suppression of the metabolic stress response by heat shock.

We next asked whether attenuation of Ser121 phosphorylation during heat shock contributes to HSF1 activation. Compared to cells expressing HSF1^WT^, cells expressing HSF1^S121A^ exhibited elevated *HSP* mRNAs, HSF1--DNA binding, and reporter activities under both basal and heat shock conditions (Fig[5F](#fig05){ref-type="fig"}--[H](#fig05){ref-type="fig"} and Supplementary [Fig S5B](#sd1){ref-type="supplementary-material"}). Under basal conditions, expression levels of HSF1^WT^ and HSF1^S121A^ were comparable and, therefore, heightened activity of HSF1^S121A^ was at least in part due to its enhanced nuclear translocation (Supplementary [Fig S5C](#sd1){ref-type="supplementary-material"} and [D](#sd1){ref-type="supplementary-material"}). Following heat shock, both HSF1^WT^ and HSF1^S121A^ proteins slightly increased (Supplementary [Fig S5C](#sd1){ref-type="supplementary-material"}). Interestingly, HSF1^S121A^ mutants increased more compared to HSF1^WT^ (Supplementary [Fig S5C](#sd1){ref-type="supplementary-material"}), congruent with a role of Ser121 phosphorylation in HSF1 stability. This elevated protein levels may also contribute to heightened HSF1 activities in cells expressing HSF1^S121A^ under heat shock conditions, in addition to enhanced nuclear translocation (Supplementary [Fig S5D](#sd1){ref-type="supplementary-material"}). Together, these results indicate that proteotoxic stress suppresses AMPK, which facilitates the PSR but impairs cellular responses to metabolic stressors. Intriguingly, metabolic and proteotoxic stressors exert opposite impacts on AMPK and HSF1 (Fig[5I](#fig05){ref-type="fig"}).

Metabolic stressors disrupt proteostasis in tumor cells
-------------------------------------------------------

Our and others\' recent studies have pinpointed HSF1 as a potent facilitator of oncogenesis (Dai *et al*, [@b10], [@b12]; Min *et al*, [@b46]; Meng *et al*, [@b45]; Jin *et al*, [@b33]; Scott *et al*, [@b56]). In light of our new findings, we next asked whether HSF1 inactivation could contribute to the anti-neoplastic effects of metabolic stressors.

First, we examined the impact of 10 μM metformin, a clinically relevant concentration, on constitutive HSF1 activation in tumor cells. In WM115 and WM278 human melanoma cells, metformin impaired constitutive endogenous HSF1--DNA binding (Fig[6A](#fig06){ref-type="fig"}) and diminished basal mRNA levels of *HSP72/HSPA1A* and *HSP27/HSPB1* (Fig[6B](#fig06){ref-type="fig"}). Conversely, *AMPK*α*1/2* suppression not only elevated basal *HSP* expression but also antagonized metformin-mediated *HSP* suppression (Fig[6C](#fig06){ref-type="fig"} and [D](#fig06){ref-type="fig"}). Compound C at 2 μM exerted similar effects, albeit to a lesser extent (Supplementary [Fig S6A](#sd1){ref-type="supplementary-material"} and [B](#sd1){ref-type="supplementary-material"}). To demonstrate HSP reduction at the protein level by metformin in tumor cells, prolonged treatment was applied to both block new synthesis of HSPs and deplete existing HSPs. Indeed, this prolonged treatment diminished HSP72 and HSP27 protein levels in a panel of diverse human tumor cell lines, ranging from melanoma (WM115 and A2058), to malignant peripheral nerve sheath tumor (MPNST) (S462), to colon carcinoma (RKO), and to breast adenocarcinoma (MCF-7 and MDA-MB-231) (Fig[6E](#fig06){ref-type="fig"}; Supplementary [Fig S6C](#sd1){ref-type="supplementary-material"}--F).

![Metabolic stressors inactivate HSF1 and disrupt proteostasis in tumor cells A, B Following treatment with 10 μM metformin for 3 days, the levels of HSF1 binding to endogenous *HSP* promoters were quantitated by chromatin IP (mean ± SD, *n *=* *3, one-way ANOVA, \*\**P *\<* *0.01, \*\*\**P *\<* *0.001). Normal rabbit IgG served as the negative control (A). Following the same treatment, *HSP* mRNA levels were quantitated by qRT--PCR (mean ± SD, *n *=* *3, Student\'s *t*-test, \*\*\**P *\<* *0.001) (B).C, D Following transfection with *AMPK*α*1/2*-targeting siRNAs for 2 days, WM115 cells were treated with 10 μM metformin for 3 days. *HSP* mRNA levels were quantitated by qRT--PCR (mean ± SD, *n *=* *6, Student\'s *t*-test, n.s., not significant, \**P *\<* *0.05, \*\**P *\<* *0.01).E Following treatment with 10 μM metformin for 7 days, protein levels in WM115 and S462 cells were measured by immunoblotting.F, G Following treatment with 10 μM metformin for 7 days, levels of polyubiquitinated proteins were detected in both detergent-soluble and detergent-insoluble fractions in WM115 and A2058 cells using a Lys48-specific polyubiquitin antibody.H A2058 cells were treated with 10 μM metformin alone or co-treated with 2 μM compound C for 7 days. Individual proteins were detected by immunoblotting.I HEK293T cells stably expressing either scramble or *HSF1*-targeting shRNAs were treated with 10 μM metformin for 7 days. Individual proteins were detected by immunoblotting.J In HEK293T cells, a plasmid encoding HA-polyQ79-GFP was co-transfected with the indicated plasmids. Following treatment with and without 10 μM metformin for 5 days, the sizes of aggregates in detergent-insoluble fractions were quantitated by a Multisizer™ 3 Coulter Counter. Experimental details are described in Materials and Methods.K, L Immortalized and *RAS*-transformed MEFs were treated with either 10 μM metformin (K) or different concentrations of glucose (L) for 7 days. Individual proteins were detected by immunoblotting.M Following transfection with LacZ or polyQ79, HEK293T cells were grown under different concentrations of glucose for 5 days before measuring aggregate size.\
Source data are available online for this figure.](embj0034-0275-f6){#fig06}

Consistent with diminished HSP levels, metformin treatment elevated global protein Lys48 polyubiquitination in both detergent-soluble and detergent-insoluble fractions in diverse human tumor cell lines (Fig[6F](#fig06){ref-type="fig"} and [G](#fig06){ref-type="fig"}; Supplementary [Fig S6G](#sd1){ref-type="supplementary-material"}--I). Importantly, co-treatment with compound C prevented HSP reduction, elevation of polyubiquitination, and increase in caspase 3 cleavage, which indicates apoptosis (Fig[6H](#fig06){ref-type="fig"}). These results demonstrated a key role of AMPK in metformin-induced proteostasis disruption. Importantly, while *HSF1* knockdown reduced HSP expression and elevated protein polyubiquitination, treatment of *HSF1*-deficient cells with metformin failed to further induce polyubiquitination (Fig[6I](#fig06){ref-type="fig"}), indicating that metformin disrupts proteostasis mainly through HSF1 suppression. Increased ubiquitination of detergent-insoluble proteins suggested aggravated protein aggregation (Fig[6F](#fig06){ref-type="fig"}--[I](#fig06){ref-type="fig"}). To investigate this effect of metformin in detail, we developed a new method to measure intracellular protein aggregation. Our method is based on the Coulter principle, which detects the alterations in electrical impedance produced by particles suspended in an electrolyte (Zwicker, [@b72]), and which we adapted to quantitate the sizes of protein aggregates extracted from live cells. To use this method to quantitate protein aggregation, we measured aggregation of the GFP-tagged polyglutamine expansion tract (polyQ79) protein (Sanchez *et al*, [@b54]). Proteins with polyQ expansions are prone to misfolding and aggregation and are casually implicated in human neurodegenerative disorders (Muchowski & Wacker, [@b49]). While LacZ-expressing HEK293T cells contained only small aggregates that were barely detectable, polyQ79 expression markedly enlarged aggregates (Fig[6J](#fig06){ref-type="fig"}), validating our new approach for aggregate quantitation. Importantly, both metformin and AMPKα^CA^ further enlarged these aggregates (Fig[6J](#fig06){ref-type="fig"}), congruent with diminished HSP levels. Conversely, either HSF1 or a dominant negative AMPK mutant, AMPKα^DN^ (Mu *et al*, [@b48]), potently antagonized the enlargement of aggregates by metformin (Fig[6J](#fig06){ref-type="fig"}), strongly suggesting a critical role of the AMPK--HSF1 pathway in metformin-induced protein aggregation. In further support of an aggravated protein aggregation, metformin caused a shift in distribution of polyQ proteins from detergent-soluble to detergent-insoluble fractions (Supplementary [Fig S6J](#sd1){ref-type="supplementary-material"}).

We previously demonstrated that HSF1 is essential to the growth and survival of tumor cells but dispensable for primary non-transformed cells (Dai *et al*, [@b10]). We reasoned that malignant cells might be more sensitive to metformin treatment than their non-transformed counterparts. To test this, we employed a pair of isogenic cell lines: immortalized MEFs and malignant derivatives of these cells that stably express oncogenic *HRAS*^*G12V*^. In malignant MEFs, metformin impaired HSP72 expression, elevated protein polyubiquitination, and induced caspase 3 cleavage; in contrast, metformin had little effect on immortalized MEFs (Fig[6K](#fig06){ref-type="fig"}). Interestingly, glucose deprivation exerted similar effects (Fig[6L](#fig06){ref-type="fig"}) as well as aggravated polyQ aggregation (Fig[6M](#fig06){ref-type="fig"}), all in a dose-dependent manner. Collectively, these results indicate that metabolic stressors suppress the HSF1-mediated PSR in malignant cells, thereby impairing their proteostasis and survival.

Metformin inactivates HSF1 to retard tumor growth *in vivo*
-----------------------------------------------------------

Consistent with an HSF1 dependence of malignant cells, stable *HSF1* knockdown markedly impaired proliferation of A2058 and S462 cells (Fig[7A](#fig07){ref-type="fig"}; Supplementary [Fig S7A](#sd1){ref-type="supplementary-material"}). This impairment was correlated with aggravated protein polyubiquitination (Fig[7B](#fig07){ref-type="fig"}). In line with a role in HSF1 inactivation, the proliferation of A2058 and S462 cells was also impaired by metformin (Fig[7C](#fig07){ref-type="fig"}; Supplementary [Fig S7B](#sd1){ref-type="supplementary-material"}). Of note, the anti-proliferation effect of metformin was more robust under low and normal glucose conditions than under high glucose conditions (Fig[7C](#fig07){ref-type="fig"}; Supplementary [Fig S7B](#sd1){ref-type="supplementary-material"}), indicating a modifying effect of nutrients on metformin efficacy and consistent with a previous report (Javeshghani *et al*, [@b32]). Importantly, HSF1 overexpression significantly antagonized metformin-induced proliferation inhibition under normal and low glucose conditions (Fig[7C](#fig07){ref-type="fig"}; Supplementary [Fig S7B](#sd1){ref-type="supplementary-material"}).

![Metformin inactivates HSF1 to retard tumor growth A, B A2058 cells were transduced with lentiviral scramble or *HSF1*-targeting (hA6 and hA9) shRNAs. (A) Cell numbers were quantitated by Hoechst 33342 DNA staining (mean ± SD, *n *=* *4, two-way ANOVA, \*\*\**P *\<* *0.001). (B) Protein levels were measured by immunoblotting.C A2058 cells stably expressing LacZ or HSF1 were grown in medium containing 4.5, 1.0, or 0.45 g/l glucose. Following treatment with 10 μM metformin, cell proliferation was measured by Hoechst 33342 DNA staining (mean ± SD, *n *=* *5, two-way ANOVA, \*\*\**P *\<* *0.001).D, E 1 × 10^6^ LacZ- or HSF1-expressing A2058 cells were transplanted into female NOD/SCID mice. One day after transplantation, metformin was administered via drinking water at 1 mg/ml. Tumor incidence (log-rank test; D) and volumes (E) were measured (mean ± SEM, two-way ANOVA n.s., not significant, \**P *\<* *0.05, \*\**P *\<* *0.01, \*\*\**P *\<* *0.001). Tumor growth curves were fitted to exponential growth models to calculate tumor doubling time (DT).F Individual proteins were measured by immunoblotting using lysates of three tumors from each treatment group.G Protein levels were measured by immunoblotting using lysates of mouse liver tissues.H A2058 cells stably expressing FLAG-HSF1^WT^ or FLAG-HSF1^S121A^ were treated with 10 μM metformin for 7 days. Protein levels were measured by immunoblotting.I A2058 cells stably expressing HSF1^WT^ or HSF1^S121A^ were grown in Corning®ultra-low attachment 96-well culture plates with 10 μM metformin and different concentrations of glucose for 7 days, 10,000 cells per well. Viable cells were counted by Guava flow cytometer using ViaCount® reagent (mean ± SEM, *n *=* *8, Student\'s *t*-test, n.s., not significant, \*\**P *\<* *0.01, \*\*\**P *\<* *0.001).J Tukey box plots showing the inverse correlation between AMPKα Thr172 phosphorylation and *HSP* mRNA expression in ccRCC. Patients were stratified on the median value of AMPKα Thr172 phosphorylation reverse-phase protein array (RPPA) scores (Student\'s *t*-test).K Schematic depiction of the suppression of HSF1 and disruption of proteostasis by AMPK in malignant transformation.\
Source data are available online for this figure.](embj0034-0275-f7){#fig07}

To examine the metformin--HSF1 interaction *in vivo*, we established a human melanoma xenograft model in NOD/SCID mice using A2058 cells that stably overexpressed either LacZ or HSF1. To provide clinical relevance, mice were administered metformin through drinking water at a concentration equivalent to the daily dose taken by T2D patients. Without metformin treatment, HSF1-expressing A2058 cells exhibited accelerated *in vivo* growth, evidenced by increased tumor incidence, volume, and mass, compared to LacZ-expressing cells (Fig[7D](#fig07){ref-type="fig"} and [E](#fig07){ref-type="fig"}; Supplementary [Fig S7C](#sd1){ref-type="supplementary-material"} and [D](#sd1){ref-type="supplementary-material"}). Congruently, mice harboring HSF1-expressing cells exhibited shortened survival (Supplementary [Fig S7E](#sd1){ref-type="supplementary-material"}). These results demonstrate the pro-oncogenic role of HSF1. Congruent with its reported anti-neoplastic effects, metformin retarded the *in vivo* growth of both LacZ- and HSF1-expressing cells (Fig[7D](#fig07){ref-type="fig"} and [E](#fig07){ref-type="fig"}; Supplementary [Fig S7C](#sd1){ref-type="supplementary-material"} and [D](#sd1){ref-type="supplementary-material"}). Importantly, HSF1-expressing tumors were less responsive to metformin treatment, indicated by less inhibited tumor incidence rate (30% vs. 58% inhibition in LacZ-expressing tumors; Supplementary [Fig S7C](#sd1){ref-type="supplementary-material"}), less prolonged tumor doubling time (32% vs. 61% prolongation in LacZ-expressing tumors; Fig[7E](#fig07){ref-type="fig"}), and less reduced tumor mass (50% vs. 67% reduction in LacZ-expressing tumors; Supplementary [Fig S7D](#sd1){ref-type="supplementary-material"}). These results indicate partial metformin resistance engendered by HSF1. At the molecular level, metformin provoked proteotoxic stress, cell death, and AMPK activation in tumors, indicated by elevated protein polyubiquitination, caspase 3 cleavage, and AMPKα phosphorylation (Fig[7F](#fig07){ref-type="fig"}). As expected, both AMPKα Thr172 and HSF1 Ser121 phosphorylation were elevated in metformin-treated tumors; interestingly, total HSF1 levels were also diminished by chronic metformin treatment (Fig[7F](#fig07){ref-type="fig"}), congruent with HSF1 destabilization by metformin. Importantly, HSF1 overexpression not only potently antagonized these metformin-induced changes but also suppressed proteotoxic stress and cell death under basal conditions (Fig[7F](#fig07){ref-type="fig"}). In sharp contrast, metformin did not provoke proteotoxic stress and cell death in normal mouse livers (Fig[7G](#fig07){ref-type="fig"}; Supplementary [Fig S7F](#sd1){ref-type="supplementary-material"}), demonstrating a distinct sensitivity of tumor tissues to metformin. Given that chronic metformin treatment induced both Ser121 phosphorylation and depletion of HSF1 in tumors, we further investigated the importance of Ser121 phosphorylation in metformin-mediated anti-neoplastic effects. To address this, we generated a pair of isogenic A2058 cell lines, in which endogenous HSF1 was substituted with either FLAG-HSF1^WT^ or FLAG-HSF1^S121A^. These engineered cell lines expressed comparable levels of HSF1 (Supplementary [Fig S7G](#sd1){ref-type="supplementary-material"}). Whereas metformin markedly suppressed HSP expression and induced protein ubiquitination in HSF1^WT^-expressing cells, these effects were largely abolished in HSF1^S121A^-expressing cells (Fig[7H](#fig07){ref-type="fig"}). In consequence, the proliferation of HSF1^S121A^-expressing cells was less impaired by metformin compared to that of HSF1^WT^-expressing cells under adherent conditions (Supplementary [Fig S7H](#sd1){ref-type="supplementary-material"}). Moreover, HSF1^S121A^-expressing cells were also more resistant to metformin treatment under anchorage-independent growth conditions. This was demonstrated in both suspension cultures and soft agar assays (Fig[7I](#fig07){ref-type="fig"} and Supplementary [Fig S7I](#sd1){ref-type="supplementary-material"}). While in suspension cultures, cells expressing HSF1^WT^ were sensitive to metformin at all glucose concentrations, they only responded to metformin at normal and low glucose concentrations in soft agar (Supplementary [Fig S7I](#sd1){ref-type="supplementary-material"}). Of note, glucose concentrations had a marked impact on cellular growth in soft agar. In low-glucose medium, the growth of both HSF1^S121A^- and HSF1^WT^-expressing cells was severely impaired (Supplementary [Fig S7I](#sd1){ref-type="supplementary-material"}). Nonetheless, a slight metformin resistance was still observed in HSF1^S121A^-expressing cells (Supplementary [Fig S7I](#sd1){ref-type="supplementary-material"}). We reasoned that such stringent growth conditions might alleviate cellular dependence on HSF1, which is distinct from suspension growth conditions (Fig[7I](#fig07){ref-type="fig"}). These results together suggest that HSF1 Ser121 phosphorylation plays an important role in metformin-mediated anti-neoplastic effects.

Evidence from human patients also supported the AMPK-HSF1 interaction. In a large-cohort study of patients developing clear cell renal cell carcinomas (ccRCC) (Cancer Genome Atlas Research Network, [@b5]), tumors showing elevated AMPKα Thr172 phosphorylation displayed reduced mRNA levels of *HSPA1A*, *HSPA1B*, *HSPB1*, and *HSP90AA1*, all of which are classic HSF1 transcriptional targets (Fig[7J](#fig07){ref-type="fig"}), suggesting inhibition of HSF1. Moreover, ccRCC patients with high levels of AMPKα phosphorylation demonstrated better overall survival (Supplementary [Fig S7J](#sd1){ref-type="supplementary-material"}; Cancer Genome Atlas Research Network, [@b5]). Taken together, these results indicate that a clinically relevant concentration of metformin suppresses constitutive HSF1 activation and disrupts proteostasis within tumor cells, thereby retarding tumor growth (Fig[7K](#fig07){ref-type="fig"}).

Discussion
==========

Our findings unveil a novel interplay between AMPK and HSF1. AMPK inactivates HSF1 through phosphorylation of it at Ser121. This regulation, remarkably, impacts stress resistance, proteostasis, and malignant growth.

HSF1 at the crossroads of the metabolic and proteotoxic stress responses
------------------------------------------------------------------------

In response to fluctuations of intracellular AMP and ATP levels, AMPK critically preserves energy homeostasis by stimulating ATP production and suppressing ATP consumption (Hardie, [@b25]). This metabolic switch driven by AMPK enables cells to survive energy stress. To survive and adapt to such stress, it is imperative for cells to downscale anabolic processes such as lipid and protein production. Metabolic stress activates AMPK, which subsequently inhibits activities of SREBP1 and mTORC1 (Gwinn *et al*, [@b24]; Li *et al*, [@b41]), key regulators of lipid and protein synthesis. Significantly, our findings indicate that AMPK likely plays an additional key role in survival of metabolic stress. Similar to the case with lipid and protein synthesis, processes involved with chaperone-mediated protein folding and anti-aggregation also consume ATP (Welch, [@b67]). It becomes wasteful energetically to sustain excessive chaperoning capacity when overall protein synthesis is mitigated, as is the case during times of stress. Therefore, it is a logical action of cells to diminish chaperone production, through inactivation of HSF1, in the face of metabolic stress. Thus, our findings expand the roles of AMPK in protein metabolism beyond mTORC1-mediated translational control and reveal that by gauging cellular energy status, AMPK finely orchestrates protein quantity and quality control machineries. In this sense, our findings suggest attenuation of the PSR as an integral part of the cellular adaption to metabolic stress.

Inactivation of HSF1 by amino acid starvation was reported previously (Hensen *et al*, [@b27]), although the underlying mechanisms remained elusive. Now, our findings reveal that the metabolic and proteotoxic stress responses, two fundamental cellular stress pathways, are interconnected through AMPK and HSF1. Whereas metabolic stressors activate AMPK but suppress HSF1, our results reveal that proteotoxic stressors, such as heat shock, exert the opposite effects at least in the cell types we examined (Fig[5I](#fig05){ref-type="fig"}). Although the response to each individual stress is advantageous to survival of that stress, this antagonizing interaction between the two responses could have adverse impacts in the face of simultaneous exposure to the two stresses (Figs[4E](#fig04){ref-type="fig"} and [F](#fig04){ref-type="fig"}, and [5D](#fig05){ref-type="fig"} and [E](#fig05){ref-type="fig"}). While our results indicate diminished AMPK activities under heat shock in NIH3T3 and HEK293 cells (Fig[5A](#fig05){ref-type="fig"}--[C](#fig05){ref-type="fig"}; Supplementary [Fig S5A](#sd1){ref-type="supplementary-material"}), it was previously reported that heat shock activated AMPK in rat hepatocytes (Corton *et al*, [@b8]), a highly metabolically active cell type. Thus, these results suggest that AMPK response to heat stress may be cell type dependent.

Implications of AMPK--HSF1 interactions in human diseases and therapies
-----------------------------------------------------------------------

Evidence is emerging that implicates AMPK in neurodegeneration. Neuronal AMPK activation has been noted in Huntington\'s disease and Alzheimer\'s disease and contributes to neuronal death (Ju *et al*, [@b35]; Vingtdeux *et al*, [@b62]). Thus, it is tantalizing to speculate that AMPK activation may aggravate neurodegeneration in part through impairment of neuronal proteostasis. Exacerbation of polyQ aggregation inflicted by metformin, glucose deprivation, or activated AMPK (Fig[6J](#fig06){ref-type="fig"} and [M](#fig06){ref-type="fig"}) supports this possibility. Further, our findings imply a potential adverse side effect of metformin on populations afflicted with neurodegenerative disorders, a notion that may deserve further investigation.

Despite the importance of the HSF1-mediated PSR in oncogenesis, it remains poorly understood how malignant cells hijack this powerful adaptive mechanism. The negative regulation of HSF1 by AMPK, thus, may shed new light on this question. Previous studies have demonstrated many anti-neoplastic effects of the LKB1--AMPK pathway. LKB1 functions as a tumor suppressor and its germline mutations are causally linked to Peutz--Jeghers syndrome (Shackelford & Shaw, [@b57]). In addition, AMPK stimulates tumor suppressors including TSC2 and TP53 (Inoki *et al*, [@b31]; Jones *et al*, [@b34]), and its inactivation promotes oncogenesis (Faubert *et al*, [@b19]). Now our findings reveal an important role of the tumor-suppressive AMPK pathway in inactivating HSF1. Conceivably, inactivation of the LKB1--AMPK pathway could in a cell-autonomous fashion mobilize the PSR to assist malignant transformation. This resonates with the interaction between HSF1 and the tumor suppressor NF1 we discovered recently, in which *NF1* deficiency sufficiently activates HSF1 to promote oncogenesis (Dai *et al*, [@b12]). These negative regulations of HSF1 mediated by tumor-suppressive pathways highlight the notion that activation of HSF1 and its mediated PSR is deeply embedded within oncogenic processes.

Our findings also uncover a novel mechanism of action of metformin. The principal metabolic effects of metformin result from suppressed liver gluconeogenesis and enhanced muscle glucose uptake (Viollet *et al*, [@b63]). In addition to these well-known anti-diabetic benefits, epidemiological studies have revealed reduced tumor incidence in T2D patients taking metformin (Evans *et al*, [@b18]; Garrett *et al*, [@b20]; Sadeghi *et al*, [@b53]). Preclinical investigations show that metformin impaired *de novo* oncogenesis in mice and impeded tumor growth in xenograft models (Anisimov *et al*, [@b1]; Memmott *et al*, [@b44]; Iliopoulos *et al*, [@b30]; Tomic *et al*, [@b61]). Despite this exciting promise, the proposed underlying mechanisms are diverse, ranging from reduced insulin levels, to suppressed mTORC1 activity, to activated TP53, and to impaired NF-κB signaling (Buzzai *et al*, [@b4]; Dowling *et al*, [@b13]; Hirsch *et al*, [@b28]).

Now our findings indicate that metformin suppresses the HSF1-mediated PSR. Importantly, due to the lack of proteotoxic stress, HSF1 is dispensable for the viability of primary cells and mice under non-stress conditions (Xiao *et al*, [@b69]; Dai *et al*, [@b10]). In stark contrast, malignant cells constantly endure proteotoxic stress from within and without and, in turn, develop an addiction to HSF1 to sustain their robustness (Dai *et al*, [@b10], [@b11]). Congruently, whereas in malignant cells a clinically relevant concentration of metformin and mild glucose deprivation suppressed constitutive HSF1 activation, aggravating proteomic imbalance and impairing survival, little impact was observed in non-transformed cells (Figs[6K](#fig06){ref-type="fig"} and [L](#fig06){ref-type="fig"}, and [7F](#fig07){ref-type="fig"} and [G](#fig06){ref-type="fig"}), indicating a promising therapeutic window. Moreover, our results showing partial resistance of tumors to metformin as a result of HSF1 expression (Fig[7D](#fig07){ref-type="fig"}--[F](#fig07){ref-type="fig"}) highlight the importance of this specific mechanism to metformin\'s overall anti-neoplastic effects and further imply that tumors with low levels of HSF1 expression may be more sensitive to metformin treatment. Our findings collectively suggest a novel unifying mechanism of action of metabolic stressors in malignancy---disruption of proteostasis via HSF1 inactivation.

Materials and Methods
=====================

An ELISA-based HSF1--DNA binding assay
--------------------------------------

Biotinylated ideal HSE (CTAGAAGCTTCTAGAAGCTTCTAG**)** oligonucleotides were self-annealed to form double-stranded DNA probes in annealing buffer (10 mM Tris, pH 7.5, 50 mM NaCl, 1 mM EDTA). To immobilize these probes for HSF1 binding, 100 μl of 500 nM biotinylated HSE probes diluted in PBS was added to neutravidin-coated 96-well plates (Thermo Scientific) and incubated at 4°C overnight. After washing with PBS once, wells were incubated with 200 μl SuperBlock blocking buffer (Thermo Scientific) at RT for 1 h. After washing with 1× DNA binding buffer (10 mM Tris, 50 mM NaCl, 1 mM EDTA, 5% glycerol, pH 7.5) once, 100 μl nuclear proteins diluted in 1× DNA binding buffer was added to each well and incubated at RT for 40 min. The captured protein--DNA binding was stabilized by immediately incubating the wells with 1% formaldehyde diluted in 1× DNA binding buffer at RT for 5 min. Following washing 3 times with 1× DNA binding buffer, each well was incubated with 100 μl rabbit polyclonal HSF1 antibody (B7109, Assay Biotechnology) diluted 1:1,000 in SuperBlock blocking buffer at RT for 2 h. After TBS-T washing, each well was incubated with HRP-conjugated anti-rabbit IgG secondary antibodies diluted in the blocking buffer at RT for 1 h. Following extensive TBS-washing, colorimetric signals were developed using 1-Step Ultra TMB-ELISA substrate (Thermo Scientific).

To validate this method, nuclear extracts of heat-shocked *Hsf1*^*+/+*^and *Hsf1*^*−/−*^ cells were used to serve as positive and negative controls, respectively. Assay specificity was further validated by pre-incubating nuclear extracts with non-biotinlyated ideal HSE or a scramble oligonucleotide of the HSE (GCGACATTATTGGTGCAACATTAC).

Bioluminescence imaging
-----------------------

Transgenic Hsp70-luc-2A-eGFP reporter mice (FVB/NJ/C57BL/6J background) were obtained from The Jackson Laboratory. Mice of the same sex at 5--6 weeks of age were treated with metformin for 3 days via i.p. injection. Six hours before bioluminescence imaging, mice were challenged with a single dose of velcade via i.p. injection. Before imaging, XenoLight RediJect D-luciferin (150 mg/kg) was i.p. injected into mice. Mice were anesthetized with isoflurane, and luminescence signals were recorded using a Xenogen IVIS® Lumina II system (Caliper Life Sciences). Images of both dorsal and ventral positions were captured. The total photon flux of each mouse was quantified using Living Image® software.

Proximity ligation assay
------------------------

Following treatments, cells were fixed with 4% formaldehyde in PBS for 15 min at RT. After blocking with 5% normal goat serum in PBS with 0.3% Triton X-100, a pair of rabbit and mouse primary antibodies were incubated simultaneously with fixed cells. To detect HSF1--DNA interactions, fixed cells were treated with 7 U/ml RNase at RT for 1 h before incubation with rabbit anti-HSF1 antibodies (H-311, Santa Cruz Biotechnology) and mouse monoclonal anti-ds DNA antibody (HYB331-01, Santa Cruz Biotechnology) overnight at 4°C. To detect phospho-AMPKα--HSF1 interactions, fixed cells were incubated with rabbit monoclonal phospho-AMPKα Thr172 antibodies (40H9, Cell Signal Technology) and mouse monoclonal HSF1 antibodies (E-4, Santa Cruz Biotechnology) overnight at 4°C. All primary antibodies were used at 1:50 dilution in blocking buffer. Following incubation with Duolink® PLA® anti-rabbit Plus and anti-mouse Minus probes (OLINK Bioscience) at 37°C for 1 h, ligation, rolling circle amplification, and detection were performed using the Duolink® In Situ Detection Reagents Red (OLINK Bioscience) as per manufacturer\'s instructions. Nuclei were counterstained with Hoechst 33342. Finally, PLA signals were documented by a Leica TCS SP5 confocal microscope.

Soluble and insoluble protein fractionation
-------------------------------------------

Equal numbers of cells were incubated with cell lysis buffer containing 1% Triton X-100 on ice for 20 min. The crude lysates were first centrifuged at 500 *g* for 2 min at 4°C. The supernatants were further centrifuged at 20,000 *g* for 20 min at 4°C. The final supernatants and pellets were collected as detergent-soluble and detergent-insoluble fractions, respectively. Insoluble fractions were further subjected to sonication for SDS--PAGE.

Measurement of aggregate size
-----------------------------

Equal numbers of cells from different samples were lysed with cold cell lysis buffer. Following centrifugation at 20,000 *g* for 15 min at 4°C, detergent-insoluble pellets were further extracted with RIPA buffer 3 times. The final insoluble pellets were re-suspended in 10% SDS by pipetting and immediately subjected to aggregate sizing using a Multisizer™ 3 Coulter Counter equipped with a 20-μm aperture (Beckman Coulter).

Animal studies
--------------

*Ampk*α*1*^*fl/fl*^ and *Ampk*α*2*^*fl/fl*^ mutant mice on the C57BL/6J background were obtained from The Jackson Laboratory. *Hsf1* mutant mice (129SvJ/BALB/cJ) were a generous gift from Dr. Ivor Benjamin (Xiao *et al*, [@b69]) and described previously (Dai *et al*, [@b10], [@b11]).

For tumor xenograft studies, 1 × 10^6^ A2058 cells were s.c. injected into the left flanks of 9-week-old female NOD.CB17-Prkdc\<scid\>/J (NOD/SCID) mice (The Jackson Laboratory). One day after injection, mice were given 1 mg/ml metformin via water held in light-tight drinking bottles. This dose is calculated based on 1,000 mg/60 kg/day in humans. The equivalent mouse dose is 205 mg/kg/day, which corresponds to about 4 mg/day for a 20 g adult mouse consuming 4 ml water per day. Tumor sizes were measured by a caliper weekly, and tumor volumes were calculated following the formula 4/3πR^3^. All mouse experiments were performed under a protocol approved by The Jackson Laboratory Animal Care and Use Committee.

Statistical methods
-------------------

All statistical analyses were performed using Prism 5.0 (GraphPad software). Statistical significance: \**P *\<* *0.05; \*\**P *\<* *0.01; \*\*\**P *\<* *0.001.
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